History

History of EA Pharma Co., Ltd.

2021

Hidenori Yabune is appointed President & CEO

2019

The website "e-ben navi" to increase understanding about chronic constipation is launched.

2018

The chronic constipation treatment "MOVICOL®" #1 is launched in Japan.

The bile acid transporter inhibitor "GOOFICE® 5 mg Tablet" is launched in Japan.

EA Pharma Co., Ltd. obtains the "medical device manufacturing license".

2017

The ulcerative colitis treatment "RECTABUL® 2 mg Rectal Foam 14 Doses" is launched in Japan.

An additional dosage and administration of proton pump inhibitor Pariet® 5 mg Tablets, 10 mg Tablets is approved in Japan.

2016

The oral bowel cleansing agent "MOVIPREP® " #2 wins "Good Design Award 2016".

The Eisai Group's gastrointestinal disease business and the Ajinomoto Group's gastrointestinal disease business are integrated to establish EA Pharma Co., Ltd.

EA Pharma Co., Ltd. inauguration.

History of Eisai Co., Ltd.

History of former Ajinomoto Pharmaceuticals Co., Ltd.

2014

Ajinomoto Pharmaceuticals Co., Ltd. develops and Mochida Pharmaceutical Co., Ltd. launches ATEDIO®,a selective AT1 receptor blocker / long-acting calcium channel blocker.

2013

AY Pharmaceuticals Co., Ltd.*1 is inaugurated.

An oral cleansing solution for intestine MOVIPREP® launches.

2012

Stock of Ajinomoto Nutrition Co., Ltd. is assigned to Ajinomoto Co., Inc.

2010

Ajinomoto Pharmaceuticals Co., Ltd.*2 is inaugurated.

2008

Ajinomoto Nutrition Co., Ltd.*3 is inaugurated.

2005

Ajinomoto Medica Co., Ltd.*4 is inaugurated.

2002

Acquisition of Shimizu Pharmaceutical Co., Ltd.

The Company begins marketing of MITHERAPIST® Superfine Dispersed β-Glucan, a functional food.

The Company, Aventis Pharma Ltd. and Takeda Pharmaceutical Company Limited jointly develop risedronate, an osteoporosis treatment, for the Japanese market. The product is sold under the brand name Actonel® by Aventis and by Takeda under the brand name BENET®.
(The current distributor of Actonel® is Eisai Co., Ltd.)

1999

Ajinomoto Pharma Co., Ltd.*5 is inaugurated.

The Company develops nateglinide, a fast-acting postprandial hypoglycemic agent, which is sold under the brand name FASTIC® by Hoechst Marion Roussel Ltd. and by Yamanouchi Pharmaceutical Co.,Ltd. under the brand name Starsis®. Overseas, the Company enters into a licensing agreement with Novartis AG of Switzerland, which begins sales under the name Starlix® in 2001.
(The current distributors of Starsis®are Astellas Pharma Inc., respectively.)

1996

The Company develops and Hoechst Marion Roussel Japan Ltd.
launches LIVACT®, a branched-chain amino acid formula.

1995

The Company develops and Roussel Morishita launches ATELEC®, a long-acting calcium channel blocker.
(The current distributor of this product is Mochida Pharmaceutical Co., Ltd.)

1991

The Company develops and Morishita launches HEPAN ED®, an elemental diet for hepatic failure.

1986

The Company develops and Morishita launches LENTINAN, an anti-tumor drug.

1981

The Company develops and Morishita launches elemental diet ELENTAL®.

1957

Capital participation in Morishita.

1956

Ajinomoto Co., Inc. (the Company) begins production of pharmaceutical-use amino acids at its Kawasaki Plant, supplies to Morishita.

Morishita Pharmaceutical Co., Ltd. launches MORIAMIN®, the world ’s first crystalline amino acid infusion solution.

*1 AY Pharmaceuticals Co., Ltd.
A spin-off of the infusion and dialysis business units of Ajinomoto Pharmaceuticals Co., Ltd., inaugurated as a joint venture between Yoshindo Inc. (51%) and Ajinomoto Pharmaceuticals Co., Ltd. (49%). It became a wholly owned subsidiary of Yoshindo Inc. in March 2016.

*2 Ajinomoto Pharmaceuticals Co., Ltd.
A company formed by the separation of the pharmaceuticals business of the Company and merger with Ajinomoto Pharma Co., Ltd. and Ajinomoto Medica Co., Ltd. It was inaugurated as a wholly owned subsidiary of the Company that handles research and development through to production and sales.

*3 Ajinomoto Nutrition Co., Ltd.
A sales promotion company wholly owned by Ajinomoto Pharma Co., Ltd., established to develop the nursing care and home care markets and strengthen sales of medical foods. Ownership changed to 80% by the Company and 20% by Ajinomoto Pharmaceuticals Co., Ltd. in April 2010.It became a wholly owned subsidiary of Ajinomoto Co., Inc. in April 2012.

*4 Ajinomoto Medica Co., Ltd.
A company formed by the merger of Shimizu Pharmaceutical Co., Ltd. with the Production Division (Saitama and Fukushima plants) and Distribution Division of Ajinomoto Pharma Co., Ltd. to handle production and distribution for the pharmaceuticals business.

*5 Ajinomoto Pharma Co., Ltd.
The Company acquired the infusion and nutrition business of Hoechst Marion Roussel Japan Ltd. and inaugurated it as a wholly owned subsidiary.

The company name are as of those times and may be different from the latest ones.

#1 MOVICOL is registered trademark of Norgine group.

#2 MOVIPREP is registered trademark of Norgine group.

You are now leaving the EA Pharma website.

Thank you for browsing the EA Pharma website.
You are about to visit an external website.
(A new browsing window will be opened)

Click here to proceed